189 related articles for article (PubMed ID: 34785779)
1. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.
Song D; Cismas S; Crudden C; Trocme E; Worrall C; Suleymanova N; Lin T; Zheng H; Seregard S; Girnita A; Girnita L
Oncogene; 2022 Jan; 41(4):600-611. PubMed ID: 34785779
[TBL] [Abstract][Full Text] [Related]
2. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
Worrall C; Suleymanova N; Crudden C; Trocoli Drakensjö I; Candrea E; Nedelcu D; Takahashi SI; Girnita L; Girnita A
Oncogene; 2017 Jun; 36(23):3274-3286. PubMed ID: 28092675
[TBL] [Abstract][Full Text] [Related]
3. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.
Girnita L; Girnita A; Larsson O
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8247-52. PubMed ID: 12821780
[TBL] [Abstract][Full Text] [Related]
4. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
5. Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes.
Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
Oncogene; 2017 Oct; 36(41):5734-5744. PubMed ID: 28581517
[TBL] [Abstract][Full Text] [Related]
6. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.
Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Oncogene; 2008 Mar; 27(11):1629-38. PubMed ID: 17828296
[TBL] [Abstract][Full Text] [Related]
7. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
[TBL] [Abstract][Full Text] [Related]
8. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
10. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.
Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
J Biol Chem; 2005 Jul; 280(26):24412-9. PubMed ID: 15878855
[TBL] [Abstract][Full Text] [Related]
11. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
12. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
13. A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop.
Xiong L; Kou F; Yang Y; Wu J
J Cell Biol; 2007 Sep; 178(6):995-1007. PubMed ID: 17846171
[TBL] [Abstract][Full Text] [Related]
14. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
Merkel CA; da Silva Soares RB; de Carvalho AC; Zanatta DB; Bajgelman MC; Fratini P; Costanzi-Strauss E; Strauss BE
BMC Cancer; 2010 Jun; 10():316. PubMed ID: 20569441
[TBL] [Abstract][Full Text] [Related]
15. Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness.
Cismas S; Pasca S; Crudden C; Trocoli Drakensjo I; Suleymanova N; Zhang S; Gebhard B; Song D; Neo S; Shibano T; Smith TJ; Calin GA; Girnita A; Girnita L
Mol Cancer Res; 2023 Dec; 21(12):1288-1302. PubMed ID: 37584671
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.
Hashimoto T; Ichiki T; Ikeda J; Narabayashi E; Matsuura H; Miyazaki R; Inanaga K; Takeda K; Sunagawa K
Cardiovasc Res; 2011 Sep; 91(4):711-9. PubMed ID: 21498419
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
18. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]